Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier and get trading ideas, historical data, advanced options screeners, more. FREE 30 Day Trial

Stocks | Futures | Watchlist | More
or

AC Immune S.A. (ACIU)

AC Immune S.A. (ACIU)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 210,551
  • Shares Outstanding, K 83,552
  • Annual Sales, $ 0 K
  • Annual Income, $ -79,860 K
  • 60-Month Beta 0.51
  • Price/Sales 50.86
  • Price/Cash Flow N/A
  • Price/Book 1.08
Trade ACIU with:

Options Overview Details

View History
  • Implied Volatility 80.77% ( +39.51%)
  • Historical Volatility 78.79%
  • IV Percentile 85%
  • IV Rank 44.87%
  • IV High 176.48% on 06/17/22
  • IV Low 2.86% on 05/12/22
  • Put/Call Vol Ratio 0.00
  • Today's Volume 2
  • Volume Avg (30-Day) 16
  • Put/Call OI Ratio 0.37
  • Today's Open Interest 768
  • Open Int (30-Day) 762

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 3 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/22
See More
  • Average Estimate -0.23
  • Number of Estimates 2
  • High Estimate -0.23
  • Low Estimate -0.23
  • Prior Year -0.28
  • Growth Rate Est. (year over year) +17.86%

Price Performance

See More
Period Period Low Period High Performance
1-Month
2.34 +9.83%
on 11/30/22
3.10 -17.10%
on 11/17/22
-0.31 (-10.76%)
since 11/02/22
3-Month
2.30 +11.74%
on 09/21/22
3.29 -21.88%
on 09/29/22
-0.34 (-11.68%)
since 09/02/22
52-Week
2.06 +24.76%
on 06/16/22
5.40 -52.41%
on 12/28/21
-2.45 (-48.80%)
since 12/02/21

Most Recent Stories

More News
Is Ardelyx is A Buy After Slip in Early 2022

Ardelyx is relatively new to the market and was doing well until a small drug approval issue last year. Strong earnings and smart partnerships could save them

ARDX : 1.8500 (+5.71%)
CNCE : 4.86 (-1.42%)
KYKOF : 22.2800 (-2.92%)
SFOSF : 3.1300 (+0.97%)
KHTRF : 4.0600 (+2.06%)
ACIU : 2.57 (+1.98%)
BMEA : 6.96 (-2.79%)
AC Immune (ACIU) Reports Q3 Loss, Tops Revenue Estimates

AC Immune (ACIU) delivered earnings and revenue surprises of 29.17% and 457.95%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

ACIU : 2.57 (+1.98%)
THMO : 0.1189 (-9.17%)
AC Immune: Q3 Earnings Snapshot

AC Immune: Q3 Earnings Snapshot

ACIU : 2.57 (+1.98%)
Detailed Data From the Phase II Crenezumab Alzheimer’s Prevention Initiative Study in Autosomal Dominant Alzheimer’s Disease Presented at AAIC

Crenezumab was safe and well tolerated with no cases of ARIA-E observed during the up to eight-year studyAs previously reported, numerical differences...

ACIU : 2.57 (+1.98%)
AC Immune (ACIU) Reports Q2 Loss, Lags Revenue Estimates

AC Immune (ACIU) delivered earnings and revenue surprises of 0% and 100%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

ACIU : 2.57 (+1.98%)
VRTX : 321.37 (+0.19%)
AC Immune Reports Second Quarter 2022 Financial Results and Provides Corporate Update

Three clinical readouts delivered year to date; four more expected by year-endFirst patient dosed with anti-Abeta vaccine ACI-24.060 in Phase 1b/2 ABATE...

ACIU : 2.57 (+1.98%)
AC Immune Holds Annual General Meeting of Shareholders

LAUSANNE, Switzerland, June 24, 2022 (GLOBE NEWSWIRE) -- AC Immune SA (NASDAQ: ACIU), a clinical-stage biopharmaceutical company pioneering precision...

ACIU : 2.57 (+1.98%)
Roche Alzheimer's Candidate Failure Hurts Lilly, Biogen

Eli Lilly (LLY) and Biogen's (BIIB) Alzheimer's candidates, anti-amyloid beta antibodies, are in late-stage development and are expected to be launched in a few months.

BIIB : 298.90 (-0.98%)
RHHBY : 41.0800 (-0.15%)
LLY : 374.76 (+1.20%)
ACIU : 2.57 (+1.98%)
AC Immune Provides Update on Alzheimer’s Prevention Initiative Study Evaluating Crenezumab in Autosomal Dominant Alzheimer’s Disease

Crenezumab did not statistically significantly slow or prevent cognitive decline in people with a specific genetic mutation which causes early-onset...

ACIU : 2.57 (+1.98%)
AC Immune to Present at the 2022 Jefferies Healthcare Conference

LAUSANNE, Switzerland, May 31, 2022 (GLOBE NEWSWIRE) -- AC Immune SA (NASDAQ: ACIU), a clinical-stage biopharmaceutical company pioneering precision...

ACIU : 2.57 (+1.98%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Sell with a Average short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

AC Immune SA is a biopharmaceutical company. It develops, discover and design novel, proprietary medicines for prevention, diagnosis and treatment of neurodegenerative diseases. The Company's pipeline includes Crenezumab, ACI-24, Anti-Tau antibody, Morphomer Tau, Tau-PET imaging agent, Morphomer Abeta...

See More

Key Turning Points

3rd Resistance Point 2.86
2nd Resistance Point 2.74
1st Resistance Point 2.66
Last Price 2.57
1st Support Level 2.46
2nd Support Level 2.34
3rd Support Level 2.26

See More

52-Week High 5.40
Fibonacci 61.8% 4.12
Fibonacci 50% 3.73
Fibonacci 38.2% 3.34
Last Price 2.57
52-Week Low 2.06

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar